9.71

2.00% +0.19

ORIC Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

ORIC Pharmaceuticals Inc stock is currently priced at $9.71, with a 24-hour trading volume of 272.16K. It has seen a +2.00% increased in the last 24 hours and a -14.75% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.50 pivot point. If it approaches the $9.90 resistance level, significant changes may occur.

Previous Close:

$9.52

Open:

$9.77

24h Volume:

272.16K

Market Cap:

$654.67M

Revenue:

Net Income/Loss:

$-100.70M

P/E Ratio:

-4.4541

EPS:

-2.18

Net Cash Flow:

$-86.54M

1W Performance:

+20.32%

1M Performance:

-14.75%

6M Performance:

+37.15%

1Y Performance:

+87.45%

1D Range:

$9.48

$10.05

52W Range:

$4.90

$16.65

ORIC Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

ORIC Pharmaceuticals Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

650-388-5600

Address

240 East Grand Avenue, 2nd Floor, South San Francisco, CA

Employee

Twitter

Next Earnings Date

2024-05-06

Latest SEC Filings

ORIC's Discussions on Twitter

ORIC Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

ORIC Pharmaceuticals Inc Stock (ORIC) Latest News

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

GlobeNewswire Inc.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire Inc.

How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%

Zacks Investment Research

Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday

Benzinga

ORIC Pharmaceuticals Inc Stock (ORIC) Financials Data

ORIC Pharmaceuticals Inc (ORIC) Net Income 2024

ORIC net income (TTM) was -$100.70 million for the quarter ending December 31, 2023, a -12.99% decrease year-over-year.

ORIC Pharmaceuticals Inc (ORIC) Cash Flow 2024

ORIC recorded a free cash flow (TTM) of -$86.54 million for the quarter ending December 31, 2023, a -12.06% decrease year-over-year.

ORIC Pharmaceuticals Inc (ORIC) Earnings per Share 2024

ORIC earnings per share (TTM) was -$1.97 for the quarter ending December 31, 2023, a +12.44% growth year-over-year.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.